Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS
Volume 3, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejmcr.2021.100011
Keywords
Glycogen phosphorylase; Enzyme inhibition; X-ray crystallography; p -Coumaroyl glucose; Glycogen metabolism; NMR metabolomics
Categories
Funding
- European Union (European Social Fund-ESF) [MIS 5048932]
- National Research, Development and Innovation Office of Hungary [FK132222]
- European Regional Development Fund [GINOP-2.3.2-15-2016-00008]
Ask authors/readers for more resources
p-Coumaroyl glucose is a potent inhibitor of human liver GP, showing antihyperglycaemic properties by promoting glucose uptake and insulin-sensitizing state in cells, while also enhancing the conversion of glucose metabolism towards lipid metabolism and glycerol-derived components in HepG2 cells as indicated by NMR metabolomics analysis.
The binding of p-coumaroyl glucose to glycogen phosphorylase (GP; a pharmaceutical target for the development of antihyperglycaemic drugs) has been studied by kinetics, and X-ray crystallography while its effect to HepG2 cells metabolism has been assessed by NMR metabolomics. p-Coumaroyl glucose is a potent inhibitor of human liver GP with a Ki value of 213 mu\M that binds at the active site of the enzyme. Comparative structural analysis with chemically similar GP inhibitors reveals the structural basis of its inhibitory potency. NMR metabolomics analysis revealed that HepG2 cells in the presence of p-coumaroyl glucose actively response to higher glucose uptake from their environment and a display an insulin-sensitizingstate. Furthermore, NMR metabolomics analysis indicates an enhancement of gluconeogenesis towards lipid metabolism and glycerol-derived components.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available